RENO, Nev., March 12, 2012 /PRNewswire/ -- Lifeline
Biotechnologies, Inc., (Pink Sheets: LLBO) announces its
subsidiary, First Warning Systems, Inc. (FWS) has updated its
website: firstwarningsystems.com. Information on the status and the
progress of the Company is available on this site.
Jim Holmes, Lifeline's CEO said,
"FWS's website is a comprehensive source of Company information and
we plan to have continuous updates posted there. We are
moving forward on our plans to update the FWS detection device and
to automate our predictive bioinformatics algorithms. Our
management team has been expanded to assist in accelerating the
completion of development for final testing. Our focus is an
FDA medical device marketing clearance submission, possibly as
early as 2013."
About Lifeline Biotechnologies
Lifeline Biotechnologies, Inc. (OTC Market: LLBO) founded in
1994 is based in Reno, NV.
The Company has invested over $10M in
a device and process for early detection of breast tissue
abnormalities some of which are cancerous or pre-cancer.
Three patents are pending, one patent is issued and three clinical
trials with over 650 participants have been completed confirming
"Proof of Concept." www.lbti.com
About First Warning Systems
First Warning Systems, (FWS) founded in 2008, based in
Reno, NV is a subsidiary of
Lifeline Biotechnologies, Inc. (LLBO). FWS holds the
exclusive development, marketing and manufacturing licenses to
commercialize LLBO's intellectual property for the FWS product
line. The FWS product line is a device and process for early
detection of breast tissue abnormalities that lead to health risk
assessment and management. Three clinical trials with over
650 participants have achieved superior outcomes when compared to
other diagnostic protocols. FWS is planning a final, limited
clinical trial and a 510(k) device classification to validate the
fourth generation of the FWS product.
www.firstwarningsystems.com
Safe Harbor: This release includes forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933 and
Section 27E of the Securities Act of 1934. Statements contained in
this release that are not historical facts may be deemed to be
forward-looking statements. Investors are cautioned that
forward-looking statements are inherently uncertain. Actual
performance and results may differ materially from that projected
or suggested herein due to certain risks and uncertainties
including, without limitation, the ability to obtain financing,
successful development of the Company's product or market
acceptance of the product and regulatory and shareholder approval
for anticipated actions.
For more information, contact:
Jim Holmes, CEO 775-852-3222
Email: Jholmes@lbti.com
SOURCE Lifeline Biotechnologies, Inc.